Dana-Farber Cancer Institute Boston, Massachusetts
Director, Leonard P. Zakim Center for Integrative Therapies and Healthy Living Associate Professor, Medical Oncology
Investigating the link between exercise, irisin, and breast cancer development.
Higher levels of physical activity have been linked to lower risk of developing breast cancer, but the processes by which exercise could impact breast cancer are not well understood. Exercise has been shown to activate the immune system in breast cancers and in non-cancerous breast tissue. Dr. Ligibel has demonstrated that irisin, a hormone released by muscle during exercise, slows breast cancer development potentially through immune system activation. Dr. Ligibel’s research aims to integrate evidence connecting exercise, irisin, and breast cancer development to better understand the pathways through which exercise could lower disease risk.
Dr. Ligibel will first explore the impact of irisin on the immune system in a breast cancer model. They will measure irisin-induced activation of the immune system in non-cancerous breast tissue and in early breast cancer development. She and her team have completed the first round of this experiment and are currently analyzing the results.
In conjunction with the laboratory studies, Dr. Ligibel is enrolling women with dense breasts to a clinical trial to test the effects of 12-week exercise program on circulating irisin, as well as on immune and proliferative markers. Participants will undergo breast biopsies for assessment of circulating irisin before and after taking part in the exercise intervention. This trial is now open (NCT06322888) and has enrolled four participants. These projects will help to determine the mechanisms through which exercise could reduce breast cancer risk, as well as to identify new targets for the development of drugs that could prevent breast cancer.
Dr. Ligibel and her team are continuing analysis of the effects of on irisin or exercise on breast cells as well as investigating the effects of irisin on the immune landscape in benign breast tissue and in early breast tumor development. The team will continue enrollment to the clinical trial and plans to begin analysis of irisin and tissue biomarkers.
Jennifer Ligibel, MD is the director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living and is an associate professor of medical oncology at the Dana-Farber Cancer Institute. She completed her medical degree at Washington University in St. Louis, followed by a residency in internal medicine at Massachusetts General Hospital and fellowship in medical oncology at Dana-Farber Cancer Institute/Partners Cancer Care in Boston, Massachusetts. Dr. Ligibel’s currently serves as the Chair of the American Society of Clinical Oncology Cancer Care Delivery Council and the Prevention Committee Vice Chair of the Alliance for Clinical Trials in Oncology. Her research is focused on the impact of energy balance factors, such as physical activity and body weight, upon cancer risk and outcomes. Her long-term goals are to evaluate the impact of energy balance interventions, including weight loss and increased physical activity, on cancer recurrence and survival, and to determine the best methods of implementing these interventions in oncology practice.
2023
Please remember BCRF in your will planning. Learn More
